Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis.

ABSTRACT:

Background

The adverse events (AEs) of rituximab (RTX) for neuromyelitis optica spectrum disorder (NMOSD) are incompletely understood.

Aim

To collate information on the reported the AEs of RTX in NMOSD and assess the quality of evidence.

Methods

PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang Data, CBM, CNKI, VIP, clinicaltrials.gov, and so on were searched for studies with control groups as well as for case series that had assessed the RTX-associated AEs. The incidence of AEs and the comparison of AE risks among different therapies were pooled. The GRADE was developed for evidence quality.

Results

A total of 3566 records were identified. Finally, 36 studies (4 RCTs, 6 crochet studies, 2 NRCTs, and 24 case series), including 1542 patients (1299 female

SUBMITTER: Wang H 

PROVIDER: S-EPMC8689613 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature